The global GLP-1 Repurposed for Alzheimer’s Market is projected to...
Read More
The global CAR T-Cell Therapy Market was valued at USD 6,214.8 million in 2025 and is projected to expand at a strong CAGR of 15.1%, reaching approximately USD 22,034.6 million by 2035. This growth trajectory is being driven by sustained treatment demand across multiple myeloma and B-cell lymphoma indications, growing clinical focus on emerging targets such as GPRC5D, and continued development of allogeneic and off-the-shelf manufacturing platforms designed to improve treatment accessibility. The market comprises commercially available, regulatory-stage, and clinical-pipeline CAR T-cell products applied across hematological malignancies and an expanding set of solid tumor indications.
The market’s strong 15.1% CAGR reflects the continued clinical and commercial maturation of CAR T-cell therapy as an established treatment class for relapsed and refractory hematological malignancies, generating structured demand from specialized cell therapy centers above discretionary specialty biopharmaceutical demand growth. Sustained commercial performance of leading approved products including Carvykti, Breyanzi, Yescarta, and Abecma continues to support procurement volumes, while GPRC5D-targeted therapy represents a distinct and increasingly important target category particularly relevant in multiple myeloma treatment. Coverage extending across multiple CAR-T generations, cell sources, and manufacturing models underscores the breadth of clinical and manufacturing infrastructure now supporting this category.
How does multiple myeloma and B-cell lymphoma treatment demand drive the CAR T-cell therapy market?
Cell therapy centers continue to administer approved CAR T-cell products across relapsed and refractory multiple myeloma, diffuse large B-cell lymphoma, and other B-cell malignancies, establishing these indications as the largest contributors to market revenue. As clinical evidence continues to support earlier treatment line adoption, procurement associated with these hematological malignancy indications is expected to remain the dominant category through the forecast period.
What role does GPRC5D target expansion growth play in market expansion?
Biopharmaceutical developers increasingly advance GPRC5D-targeted CAR T-cell candidates as an important emerging target particularly relevant in multiple myeloma treatment, sustaining structured demand from developers pursuing differentiated target antigen strategies. Continued clinical development beyond the established BCMA and CD19 target framework is generating demand that increasingly exceeds levels attributable to conventional target antigen approaches alone.
How does allogeneic and off-the-shelf platform adoption sustain market growth?
Biopharmaceutical developers continue to invest in allogeneic, donor-derived, and iPSC-derived CAR T-cell manufacturing platforms, given that the choice between autologous and allogeneic approaches directly affects manufacturing time, cost, scalability, and treatment accessibility. Continued platform development is generating demand from developers and treatment centers pursuing improved manufacturing turnaround and broader patient access.
What is driving demand for CAR T-cell therapy in solid tumor applications?
Developers pursuing CAR T-cell candidates targeting mesothelin, HER2, and EGFR/EGFRvIII continue to extend this therapeutic modality beyond its historical hematological malignancy core, generating incremental demand among clinical-stage biopharmaceutical developers pursuing broader addressable patient populations including glioblastoma, pancreatic, and ovarian cancer.
How does next-generation CAR construct design sustain the market?
Biopharmaceutical developers increasingly advance armored, logic-gated, switchable, and dual/tandem CAR-T constructs to improve efficacy and reduce toxicity relative to conventional second-generation designs, sustaining structured demand from developers pursuing differentiated cell engineering approaches.
Which CAR T-cell therapy market segments are growing fastest?
The fastest-growing segments include GPRC5D and other emerging target antigens, allogeneic and off-the-shelf manufacturing platforms, next-generation armored and logic-gated CAR constructs, and solid tumor indications as clinical evidence continues to expand.
Key Players
Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson, Legend Biotech Corporation, 2seventy bio, Inc., Allogene Therapeutics, Inc., Autolus Therapeutics plc, Cellectis S.A., CRISPR Therapeutics AG, Precision BioSciences, Inc., Arcellx, Inc., Caribou Biosciences, Inc., Fate Therapeutics, Inc.
The CAR T-Cell Therapy Market’s strong 15.1% CAGR from USD 6,214.8 million in 2025 toward approximately USD 22,034.6 million by 2035 is anchored in sustained multiple myeloma and B-cell lymphoma treatment demand, growing GPRC5D target expansion activity, and continued allogeneic off-the-shelf platform adoption. Sustained clinical and manufacturing investment from companies including Johnson & Johnson, Legend Biotech Corporation, and Arcellx, Inc. confirms the CAR T-Cell Therapy Market will sustain strong growth through 2035.
Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.
The global GLP-1 Repurposed for Alzheimer’s Market is projected to...
Read MoreThe global Oral Neuroprotective Alzheimer’s Therapy Market to expand at...
Read MoreThe global siRNA Alzheimer’s Therapy Market is projected to expand...
Read More